Patients who scored high had significant different clinical characteristics from those with low pyroscore (Supplementary Figure S6A), especially in terms of frequency of MYCN amplifications, which is one of the most important molecular drivers for NB. This evidence concerns the gene MYCN and neuroblastoma.